Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen. - Wikidata - wikimedia - TriplyDB

Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen.

Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen.

http://www.wikidata.org/entity/Q30468622

about

Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice.Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Engineering immunity in the mucosal niche against sexually transmitted infections.Iron acquisition through the bacterial transferrin receptor.

P2860

Q21089693-2F0483CA-0A27-44AA-97D0-4B253E305D37 Q26995399-FB44BABA-A169-4A97-A375-E2D5728BDA81 Q34797176-2FD48F7D-CF11-4373-A10D-12BC07D14289 Q37156309-B06A1A1E-A1FC-49DA-AE87-BFABCCD1DC4C Q38461061-8CB43B1B-79C0-44DF-8B19-91DC670D23A5 Q38543768-544BDB4C-4036-47F0-BF7B-AF122F2D72F6 Q38748417-CC5F429A-A557-4D11-8BCC-7CF92F5C0551

P2860

Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen.

http://www.wikidata.org/entity/Q30468622

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Transferrin conjugation confer ...... rimeric gp140 vaccine antigen.

@ast

Transferrin conjugation confer ...... rimeric gp140 vaccine antigen.

@en

type

label

Transferrin conjugation confer ...... rimeric gp140 vaccine antigen.

@ast

Transferrin conjugation confer ...... rimeric gp140 vaccine antigen.

@en

prefLabel

Transferrin conjugation confer ...... rimeric gp140 vaccine antigen.

@ast

Transferrin conjugation confer ...... rimeric gp140 vaccine antigen.

@en

P1433

Q30468622-90F7135B-7FD4-47E9-867E-15970B892FC2

P1476

Q30468622-2F1709D5-3C5E-4F46-94D5-941BEF0F3344

P2093

Q30468622-1340AF25-E94B-450E-B219-1888C5FC6515

Q30468622-17F572D6-F9CA-42B8-B794-586CDDDD0BCD

Q30468622-4C9C73A3-8F8A-4B7B-B29F-4CDC1831632C

Q30468622-4F5F44F3-65E5-4B8F-B91A-DFBE0CEB58DB

Q30468622-78563612-963F-49E2-82E2-C895256515D3

Q30468622-AF5EE1D3-1C30-42AD-8828-AF4043DE6C5F

P2860

Q30468622-0039B3FF-F727-4394-836A-2D91663F07B1

Q30468622-0E1ED514-A417-45D4-B568-E6C1E6E1E8EC

Q30468622-0F6BC17F-9B14-4DD6-A152-F1D0E471B356

Q30468622-0F9E3BEE-A2E8-428A-8631-D019BFA4CB12

Q30468622-1724BC3B-03D3-4018-B3CD-3B9EBB73242E

Q30468622-26209C7B-A5F0-499F-888B-DBE2BF90A33B

Q30468622-2C032682-F831-45F3-B6D8-CC9A4FB3E853

Q30468622-3336E324-833B-449B-8DA0-046F72D11318

Q30468622-35CEF469-34B5-40F2-AE44-B04F8D545629

Q30468622-39A6A914-2F1D-48A4-971E-B11CBE0FBFE3

P304

Q30468622-CCEE809B-BDCC-4B24-B42B-C1BD175364E7

P31

Q30468622-42977059-9AC6-42E6-BE7C-5353A17F43E0

P356

Q30468622-4501BF7B-682F-4E39-856A-B907515FBA82

P407

Q30468622-1862687C-10B5-4382-B649-EE38D98F06C3

P433

Q30468622-ECF9A6AB-FDF2-45EA-848E-FECA7AF13BC9

P478

Q30468622-FFC867F1-878D-4B65-9C58-9D093F0ADE1C

P50

Q30468622-9EC8219D-0581-480F-8742-99067C119B3D

P577

Q30468622-63CAAC6E-9D06-4634-9A3C-F33399BA7851

P5875

Q30468622-1418FF24-BB68-483B-AE16-E24610579252

P698

Q30468622-192781CD-4D92-43F3-BC6F-36A2B4F9CE66

P932

Q30468622-5B37DAD0-A9B4-4253-BCBE-BEDABA2AA31C

P356

J.JCONREL.2011.11.009

P1433

Journal of Controlled Release

P1476

Transferrin conjugation confer ...... trimeric gp140 vaccine antigen

@en

P2093

D S Miranda de Stegmann

http://www.w3.org/2001/XMLSchema#string

D Stieh

http://www.w3.org/2001/XMLSchema#string

J F S Mann

http://www.w3.org/2001/XMLSchema#string

K Klein

http://www.w3.org/2001/XMLSchema#string

M P Cranage

http://www.w3.org/2001/XMLSchema#string

R J Shattock

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway

Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates

Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China.

Induction of mucosal immune responses in the human genital tract.

Recruitment of T cells to the lung in response to antigen challenge.

Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.

Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations

Regulation of adaptive immunity by the innate immune system

P304

240-249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCONREL.2011.11.009

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

158

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51830612

http://www.w3.org/2001/XMLSchema#string

P698

22119743

http://www.w3.org/2001/XMLSchema#string

P932

3314955

http://www.w3.org/2001/XMLSchema#string